Abstract
The use of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) in order to abrogate chemotherapy-induced neutropenia has become a routine part of many cancer treatment regimes. However, there are still very few data available about possible complications related to repeated or prolonged use of these agents in patients with malignant solid tumors. The authors report a child with brainstem glioma who received repeated cycles of multiagent chemotherapy with G- or GM-CSF support. During this period of 10 months, no clinical side effects were observed that could have been attributed to growth factor administration. However, postmortem histological examination revealed the presence of diffuse plasmacytosis, a rare hematological disorder in childhood. Undifferentiated plasma cells of nonmonoclonal origin could be demonstrated infiltrating bone marrow, lungs, and lymph nodes of the patient. Based on previously published in vitro and in vivo evidence on the interleukin-6 (IL-6)-mediated stimulatory effect of G- and GM-CSF on myeloma cell proliferation, the authors suggest a possible link between extensive growth factor support and the development of plasmacytosis in this patient.
References
Jan 1, 1979·Cancer·B C HortenD Stefoski
Nov 1, 1977·Cancer·C D BaroniF Mandelli
Jul 2, 1992·The New England Journal of Medicine·G J Lieschke, A W Burgess
Aug 1, 1992·European Journal of Haematology·F CelsingP Pisa
Sep 1, 1991·Chest·R C Bone
Dec 8, 1990·Lancet·R PowlesC Tiley
Jan 1, 1991·American Journal of Clinical Oncology·L KanzR Mertelsmann
Nov 15, 1988·Annals of Internal Medicine·J A GlaspyD W Golde
Nov 23, 1989·The New England Journal of Medicine·J E GroopmanD T Scadden
Jul 15, 1988·Cancer·J J KepesF S Vogel
Aug 1, 1986·Science·R P Nordan, M Potter
Jun 1, 1993·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·J R Schriber, R S Negrin
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M A Boogaerts
Jan 1, 1994·Medical and Pediatric Oncology·N M MarinaW H Meyer
Apr 1, 1993·Anti-cancer Drugs·M Bronchud